Value Sense
HALO
Halozyme Therapeutics, Inc. (HALO)
Last Price$61.4(0.0%)
Market Cap$7,773.1M
LTM EPS
$3.5
+63.6% YOY growth
NTM EPS
$4.7
+33.9% YOY growth
Current P/E
17.5x LTM
11.9x NTM
52w high P/E
24.3x LTM
14.8x NTM
52w low P/E
13.6x LTM
8.9x NTM
10Y avg P/E
1.5x LTM
(5.3x) NTM
HALO
is 10.3% overvalued
learn more -->
50+
undervalued stocks
Start beating the S&P 500

HALO Peter Lynch Chart

Crunching data... Almost there!

Best stock ideas on the market right now

With Value Sense, you can find undervalued stocks list with intrinsic value. Discover more stock market investment ideas.

Undervalued stocks right now

Undervalued stocks right now

Discover the top 20 best undervalued stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.

3M Return 32.1%
S&P Outperformance 19.1%
Next 3M Predicted Return 20.3%
Low P/E stocks

Low P/E stocks

Explore the best low P/E stocks to buy in 2025, featuring top companies trading at low P/E ratios.

3M Return 7.5%
S&P Outperformance -5.5%
Next 3M Predicted Return 10.2%
Undervalued dividend stocks

Undervalued dividend stocks

Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Mar 2025.

3M Return 28.4%
S&P Outperformance 15.4%
Next 3M Predicted Return 16.9%

Explore more intrinsic value tools hub for HALO

Earnings growth model
Peter Lynch Fair Value
Earnings Power Value
Discount rate
Ben Graham Fair Value
Reverse DCF
Relative Value
Intrinsic Value
DCF value calculator
Margin of safety

FAQ

What is Halozyme Therapeutics, Inc. earnings per share (EPS)?

Halozyme Therapeutics, Inc. earnings per share (EPS) for the twelve months ending Mar 11, 2025 was $3.5, a 63.6% increase year-over-year.

What is Halozyme Therapeutics, Inc. Price to Earnings (P/E) ratio?

As of Mar 11, 2025, Halozyme Therapeutics, Inc.'s P/E ratio is 17.5x. This is calculated by dividing the current share price of $61.4 by the Earnings per Share (EPS) for the trailing twelve months, which is $3.5. The P/E ratio indicates how much investors are willing to pay for each dollar of earnings.

Is Halozyme Therapeutics, Inc. overvalued or undervalued?

Halozyme Therapeutics, Inc. is currently considered overvalued based on its Discounted Cash Flow (DCF) valuation and Relative Valuation, which estimates its share price to be $55.1, compared to a market price of around $61.4. This suggests a potential overvaluation of 10.3%.